SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CASTELLAZZI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.012
AS - Asia 7.339
EU - Europa 4.033
SA - Sud America 1.075
Continente sconosciuto - Info sul continente non disponibili 303
AF - Africa 169
OC - Oceania 29
Totale 26.960
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.676
SG - Singapore 2.785
CN - Cina 1.840
IT - Italia 879
BR - Brasile 829
VN - Vietnam 786
HK - Hong Kong 602
DE - Germania 548
UA - Ucraina 544
PL - Polonia 475
GB - Regno Unito 419
TR - Turchia 387
FI - Finlandia 300
FR - Francia 212
BD - Bangladesh 201
JP - Giappone 184
CA - Canada 178
SE - Svezia 171
RU - Federazione Russa 153
IN - India 138
MX - Messico 99
ID - Indonesia 90
AR - Argentina 82
ZA - Sudafrica 68
AT - Austria 66
IQ - Iraq 63
NL - Olanda 61
CO - Colombia 40
CZ - Repubblica Ceca 40
PK - Pakistan 34
BE - Belgio 33
ES - Italia 33
VE - Venezuela 32
EC - Ecuador 28
UZ - Uzbekistan 27
AU - Australia 26
IR - Iran 23
SA - Arabia Saudita 22
MA - Marocco 21
PY - Paraguay 20
PH - Filippine 19
CL - Cile 17
EG - Egitto 17
LT - Lituania 17
AE - Emirati Arabi Uniti 16
KR - Corea 14
KE - Kenya 13
MY - Malesia 13
IE - Irlanda 12
JM - Giamaica 12
NP - Nepal 12
ET - Etiopia 10
KZ - Kazakistan 10
PE - Perù 10
UY - Uruguay 10
DZ - Algeria 9
HN - Honduras 9
JO - Giordania 9
A2 - ???statistics.table.value.countryCode.A2??? 8
AZ - Azerbaigian 8
IL - Israele 8
PT - Portogallo 8
RO - Romania 8
TN - Tunisia 8
AL - Albania 7
CR - Costa Rica 7
BG - Bulgaria 6
BO - Bolivia 6
EU - Europa 6
HR - Croazia 6
LB - Libano 6
TH - Thailandia 6
AO - Angola 5
DO - Repubblica Dominicana 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BY - Bielorussia 4
GT - Guatemala 4
KG - Kirghizistan 4
MD - Moldavia 4
PS - Palestinian Territory 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
BB - Barbados 3
GR - Grecia 3
HU - Ungheria 3
LV - Lettonia 3
LY - Libia 3
MN - Mongolia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
OM - Oman 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
CH - Svizzera 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
Totale 26.637
Salva come PNG Salva come JPEG
Città #
Singapore 1.697
Ashburn 1.659
San Jose 1.163
Woodbridge 1.121
Fairfield 905
Chandler 714
Beijing 615
Houston 602
Hong Kong 595
Santa Clara 582
Jacksonville 566
Warsaw 459
Council Bluffs 418
Ann Arbor 391
Seattle 335
New York 330
Wilmington 328
Cambridge 295
Los Angeles 270
Dallas 264
Ho Chi Minh City 258
Ferrara 237
Izmir 223
Nanjing 187
Hanoi 180
Tokyo 179
Milan 161
Princeton 153
Lauterbourg 132
Munich 132
Helsinki 120
Boardman 110
Shanghai 95
San Diego 89
São Paulo 87
Buffalo 83
Dearborn 78
Orem 76
The Dalles 71
Addison 65
Toronto 65
London 63
Mexico City 62
Jakarta 60
Phoenix 57
Turku 57
Brooklyn 55
Nanchang 55
Tianjin 53
Montreal 51
Vienna 51
Chicago 48
Shenyang 48
Bremen 47
Chennai 47
Atlanta 42
Changsha 42
Hebei 42
Jiaxing 42
Denver 41
Norwalk 38
Stockholm 36
Hefei 34
Johannesburg 34
Brussels 33
Frankfurt am Main 33
Haiphong 33
Bologna 32
Poplar 31
San Francisco 31
Baghdad 30
Brno 29
Rome 29
Boston 27
Falls Church 27
Moscow 26
Da Nang 24
Manchester 24
Tashkent 24
Guangzhou 22
Redwood City 22
Zhengzhou 22
Amsterdam 21
Nuremberg 21
San Mateo 21
Dong Ket 20
Jinan 20
Ningbo 20
Rio de Janeiro 20
Auburn Hills 19
Biên Hòa 19
Orange 19
Washington 19
Belo Horizonte 18
Brasília 18
Mountain View 17
Ankara 16
Caracas 16
Columbus 16
Shenzhen 16
Totale 18.030
Salva come PNG Salva come JPEG
Nome #
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment 420
Decreased Arylesterase activity of Paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases 311
Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals 310
A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis 289
Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara 285
Epstein-Barr virus and Multiple Sclerosis: in-depth analysis of the virus-specific antibody response at the time of diagnosis and during therapy 264
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker 259
Chlamydia pneumoniaespecific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms 258
Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage 257
Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients 257
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 255
Comparison of antibodies with amylase activity from cerebrospinal fluid and serum of patients with multiple sclerosis 247
Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules 247
Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment 245
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 244
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 240
Emerging topics and new perspectives on HLA-G 235
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis 233
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 229
Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders 228
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies 225
A new developed culture method efficiently supports the growth of Chamydia pneumoniae in PBMC and CSF samples from patients with Multiple Sclerosis 224
A proteomic approach to detect gelatinases levels and their inhibitors in patients with neurological diseases 224
Epidemiological health and social study on multiple sclerosis in the Ferrara province 223
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients 223
A Further Evidence Of Pathogenic Role Of Chlamydia Pneumoniae In Multiple Sclerosis 222
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis 222
Affinity distribution of anti-EBV IgG in the cerebrospinal fluid of patients with multiple sclerosis and in controls 218
Altered miRNA expression in T regulatory cells in course of multiple sclerosis 217
An overview on the relationship between Epstein-Barr virus and multiple sclerosis 213
Cerebrospinal fluid analysis and the determination of oligoclonal bands 212
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS 212
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 212
25-hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis 210
Effect of pH on MMP-9 release by LPS-stimulated neutrophils 208
Clinical and MRI activity are associated to elevated cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-9 in multiple sclerosis patients 202
Matrix metalloproteinase 9 as a marker of disease activity in multiple sclerosis 199
Neurofilament ELISA validation 199
Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients 198
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis 197
Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient 195
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 195
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy 194
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES Identification of a TIMP-1-resistant active MMP-9 in serum of Multiple Sclerosis patients 192
DNA Sequences of Parachlamydia-like organisms in CSF of Patients with Neurological Disorders 192
Altered miRNA expression in T regulatory cells in course of multipla sclerosis 188
Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. 188
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR THE IMPLEMENTATION A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES IN MS. 187
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding 187
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study 187
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings 187
Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms 183
Detection of Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response in a subset of patients with progressive forms of multiple sclerosis 183
Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients 182
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 are elevated in in multiple sclerosis patients with disease activity 181
Analysis of MMP-9 in CSF and sera of patients with neurological diseases 181
25 hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis during relapse and remission 179
CSF levels and soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis 177
Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage 176
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS - ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES. 172
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study 171
Elevated CSF and serum levels and intrathecal synthesis of active MMP-2 in MS patients with no evidence of MRI disease activity 171
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis 171
Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients 170
Biomolecular and immunological diagnostic aspects of toxoplasmosis during AIDS. 169
Intrathecal levels of vitamin D and IgG in multiple sclerosis 167
The Diagnostic Utility of Oligoclonal Bands in Multiple Sclerosis: A Time-Course Analysis 165
EBV-specific intrathecal oligoclonal antibody response in multiple sclerosis patients 165
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 164
N-acetylaspartate, glutammate and aspartate levels in multiple sclerosis cerebrospinal fluid. 162
Cerebrospinal Fluid Analysis in Rheumatological Diseases with Neuropsychiatric Complications and Manifestations: A Narrative Review 160
Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients 159
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis 158
Cerebrospinal fluid oligoclonal free light chain profiles in AIDS 157
Decrease Paraoxonase-1 (PON-1) Activities in Neurodegenerative Diseases 157
Sex Differences in Albumin Quotient and Cerebrospinal Fluid Total Protein Content Do Not Depend on Anthropometric Factors 156
Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies 156
Effect of HLA-G gene polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. 156
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms 153
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 152
Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity 151
Aspetti diagnostici biomolecolari ed immunologici della toxoplasmosi in pazienti AIDS. 150
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study 148
Cerebrospinal fluid free Kappa and Lambda lights chains in MS. A qualitative analysis 148
CSF levels of soluble classical HLA-I and non-classical HLA-G molecules in relapsing-remitting multiple sclerosis and their association with CSF IL-10 concentrations and MRI findings. 148
INTRATHECAL PRODUCTION OF ACTIVE FORM OF MATRIX METALLOPROTEINASES-9 IN PATIENTS WITH MULTIPLE SCLEROSIS: PRELIMINARY RESULTS” 147
Gelatinase: enzymatic activity as potential biomarker in multiple sclerosis 147
Low prevalence of antibodies against Simian Virus 40 in serum samples from patients affected by neurologic diseases, including multiple sclerosis 146
Chlamydia pneumonia-specific CFS-restricted oligoclonal IgG bands are associated to a subset of patients with prosessive forms of multiple sclerosis. 145
SERUM GELATINASES LEVELS IN MULTIPLE SCLEROSIS PATIENTS DURING 21 MONTHS OF NATALIZUMAB TREATMENT 145
Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients 144
Ruolo dei micro RNA nel funzionamento delle cellule T immunoregolatorie CD4 e CD25 nell'ambito della Sclerosi Multipla 143
Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology 143
Gelatinases: enzymatic activity as potential biomarker in multiple sclerosis 141
Inflammation and axonal damage biomarkers in Multiple Sclerosis: new perspective on their role 140
Potential role of soluble HLA-G molecules in multiple sclerosis 139
Intrathecal synthesis of interleukin-12 in multiple sclerosis 138
MMP-9 isoforms in serum of Multiple Sclerosis patients 136
Extracellular pH modulates the release of Matrix Metalloproteinase-9 (MMP-9) by stimulated neutrophils and its activity. 136
Sexual dimorphism in the cerebrospinal fluid total protein content 135
Totale 19.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.478
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.261
Totale 121.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.131 0 0 74 57 44 60 60 65 53 122 95 501
2022/20231.599 154 138 35 236 252 230 117 152 166 6 73 40
2023/2024956 79 88 45 25 101 187 27 85 35 25 28 231
2024/20253.531 76 79 275 142 447 302 117 159 679 385 494 376
2025/202610.539 999 379 835 1.331 1.489 715 1.331 573 970 1.091 563 263
2026/20271.225 288 556 381 0 0 0 0 0 0 0 0 0
Totale 26.960